{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:avalotcagene ontaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03641703: Phase 1/Phase 2 Interventional Terminated Hemophilia B
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02695160: Phase 1 Interventional Terminated Hemophilia B
(2016)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02396342: Phase 1/Phase 2 Interventional Completed Hemophilia B
(2015)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:ranuzifigene civaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03406104: Phase 3 Interventional Completed Leber Hereditary Optic Neuropathy
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03041324: Phase 1/Phase 2 Interventional Terminated Mucopolysaccharidosis II
(2017)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03562494: Phase 1 Interventional Completed Parkinson's Disease
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:surabgene lomparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:botaretigene sparoparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE